...
首页> 外文期刊>Medical hypotheses >Is there a causative role for tetanus toxoid vaccination in the development of allergy-like symptoms and in the increasing prevalence of atopic diseases?
【24h】

Is there a causative role for tetanus toxoid vaccination in the development of allergy-like symptoms and in the increasing prevalence of atopic diseases?

机译:破伤风类毒素疫苗的接种在过敏样症状的发展和特应性疾病的患病率增加中是否具有致病作用?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Allergic diseases are a worldwide health problem. They mainly affect people living in developed countries where an increasing prevalence of allergy symptoms has been recorded in the last 20-30 years. The cause of this increase is still disputed, and, among others, the "hygiene hypothesis" supported the concept that relevant changes in lifestyle could have a relationship with the phenomenon. More recently the recorded parallel increase in autoimmune diseases has suggested to consider the hygiene hypothesis immune system leading to both allergy and to autoimmunity. Here are reported a series of observations, evidence, and data from the literature leading to a different hypothesis. The key points are: (1) the presence of two subsets of patients having allergy symptoms based on an IgE-mediated mechanism or not; (2) the positive results obtained with the autologous serum skin test in either cutaneous or respiratory affected subjects, mainly in children and adult females; (3) the presence of IgG autoantibodies against the alpha-chain of the high affinity IgE receptor (FcepsilonRIalpha) in non-IgE-mediated urticaria and even in respiratory subjects; (4) the cross-reactivity between epitopes of the tetanus toxoid molecule and the FcepsilonRIalpha detected by means of an alpha-chain affinity purified IgG fraction; (5) the positive skin reactivity obtained using IgG anti-tetanus toxoid preparations in allergic and non-allergic volunteers. The presence of IgG autoantibodies actively generated by the population-based vaccination with tetanus toxoid could induce both mediator release from activated mast cell and Th2 cytokine production early in life. There are epidemiological evidences that tetanus toxoid vaccination could be linked with an increased tendency to have allergy symptoms. The different epidemiological distribution of non-IgE-mediated symptoms, mainly affecting young infants would be in agreement with the present hypothesis. The prevalent mother-to-child relationship in terms of risk for allergysymptoms could be explained with the trans-placenta transfer of IgG. A similar transfer could also take place through the mother milk during breast feeding. It may thus be hypothesized that the increased prevalence of allergic diseases could be caused by the generalized tetanus toxoid immunization procedure, progressively extended to most of the countries worldwide in the last 30-40 years. Both the induction of non-IgE-mediated symptoms caused by the mast cell activation via the anti-FcepsilonRIalpha IgG and the long lasting Th2 inflammation of affected tissues would be the inducing mechanisms. This hypothesis would re-configure part of the allergic diseases as a Th2 phenotypic expression of an autoimmune disease.
机译:过敏性疾病是全球性的健康问题。它们主要影响生活在发达国家的人们,在过去的20至30年中,过敏症状的患病率呈上升趋势。这种增加的原因仍然存在争议,除其他外,“卫生假说”支持这样一种观念,即生活方式的相关变化可能与该现象有关。最近,已记录的自身免疫性疾病平行增加提示,应考虑导致过敏和自身免疫的卫生假说免疫系统。这里报道了来自文献的一系列观察,证据和数据,得出了不同的假设。关键点是:(1)是否存在基于IgE介导的机制的具有过敏症状的患者的两个子集; (2)在皮肤或呼吸道感染的受试者中,主要在儿童和成年女性中,通过自体血清皮肤试验获得的阳性结果; (3)在非IgE介导的荨麻疹中,甚至在呼吸道受试者中,针对高亲和力IgE受体(FcepsilonRIalpha)的α链的IgG自身抗体的存在; (4)通过α链亲和纯化的IgG级分检测破伤风类毒素分子的表位与FcepsilonRIα之间的交叉反应性; (5)在过敏和非过敏志愿者中使用IgG抗破伤风类毒素制剂获得的阳性皮肤反应性。破伤风类毒素的基于人群的疫苗接种可主动产生IgG自身抗体,可诱导生命早期激活的肥大细胞释放介质和产生Th2细胞因子。流行病学证据表明,破伤风类毒素疫苗接种可能与过敏症状的增加趋势有关。非IgE介导症状的主要流行病学的不同流行病学分布将与当前的假设相符。关于变态反应症状的风险,流行的母婴关系可以通过IgG的胎盘转运来解释。在母乳喂养期间,母乳也可能发生类似的转移。因此,可以假设过敏性疾病的患病率增加可能是由广泛的破伤风类毒素免疫程序引起的,在过去的30-40年中,这种程序逐渐扩展到了世界上大多数国家。通过抗FcepsilonRIalpha IgG引起的肥大细胞活化引起的非IgE介导的症状的诱导和受影响组织的持久Th2炎症都将是诱导机制。该假设会将部分过敏性疾病重新配置为自身免疫性疾病的Th2表型表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号